A decline in back muscle mass is linked to poor clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF), and can be used as an independent predictor of disease prognosis, a study found. The study, “Early decrease…
News
Starting a 501(c)(3) tax-exempt nonprofit isn’t easy, but the National Organization for Rare Disorders gave a few tips for those  looking to begin the complex process in its Feb. 20 webinar. William Whitman…
Although 50,000 new cases of pulmonary fibrosis (PF) are diagnosed each year, a national survey found that 86 percent of U.S. residents are unfamiliar with the disease’s symptoms. The online National Awareness Survey from the Pulmonary Fibrosis Foundation (PFF), was completed by 2,013 U.S. adults, and…
Researchers at the University of Pittsburgh and the University of Delaware received funding for their research into innovative therapies for specific disease areas, including pulmonary fibrosis (PF). CSL Behring and the University City Science Center awarded $250,000 each to Cecelia Yates, PhD, from the University…
Hepion Pharmaceuticals‘ CRV431 lowers the production of fibrosis-associated proteins in a variety of cell types, including lung cells, new data from the company show. CRV431 is a small molecule being developed as an investigational treatment for non-alcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease. Both of these conditions are…
Use of INOpulse — inhaled nitric oxide — lessened pulmonary arterial pressure, and the resistance to blood flow in arteries that supply blood to the lungs, in people with pulmonary hypertension (PH) associated with pulmonary fibrosis (PH-PF), top-line results from a Phase 2 trial show. These results add to…
An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought to affect. Patients, caregivers, and advocates worldwide will sport denim ribbons…
During the course of her mother’s six-year battle with idiopathic pulmonary fibrosis (IPF), caregiver Taleena Koch felt alone. Now Koch, 54, hopes to change that feeling for the thousands of people involved in her Breathe Support Network. Her nonprofit group offers an online discussion…
High levels of the protein osteopontin in the blood are associated with acute exacerbations and a higher risk of death in people with idiopathic pulmonary fibrosis (IPF), a study found. These findings suggest that osteopontin may potentially be used in the future as a biomarker of IPF…
In the U.S., 61% of people with idiopathic pulmonary fibrosis (IPF) are prescribed approved anti-fibrotic therapies, namely Ofev (nintedanib) and Esbriet (pirfenidone), analysis of data from the U.S. Pulmonary Fibrosis (PF) Foundation Patient Registry shows. In turn, almost 40% of IPF patients are not prescribed either…
